QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
NCT07775846 on ClinicalTrials.gov · last registry update 2026-08-20
An unusually large phase 4: 820 participants, more than double the 75 typical for the stage. Due to report 28 February 2029, alongside 11 other tracked readouts that quarter. Primary outcome, as filed: Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Month 6. Sponsors move these dates routinely; any movement since this site started watching is listed below. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- mazdutide
- Sponsor
- Huijie Zhang
- Sponsor type
- Other
- Enrollment
- 820
- Started
- 2026-09-01
- Primary completion
- 2029-02-28 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Month 6
Conditions studied
Type 2 Diabetic Kidney Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.